{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T18:14:16Z","timestamp":1792174456236,"version":"4.4.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,10,26]],"date-time":"2019-10-26T00:00:00Z","timestamp":1572048000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,10,26]],"date-time":"2019-10-26T00:00:00Z","timestamp":1572048000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["MSIP No. 2014R1A5A2010008"],"award-info":[{"award-number":["MSIP No. 2014R1A5A2010008"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"crossref","award":["NRF-2017R1D1A1B03032729"],"award-info":[{"award-number":["NRF-2017R1D1A1B03032729"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2020,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n<jats:p>Obesity is growing rapidly worldwide due to consumption of westernized diet and lack of exercise. Obesity is one of the major risk factors of hypertension. The novel histone deacetylase (HDAC) inhibitor CG200745 was originally developed to treat various cancers. Previous studies showed that CG200745 attenuated hypertension through inhibition of cardiac hypertrophy and fibrosis in deoxycorticosterone acetate-induced hypertensive rat. The purpose of this study is to investigate the role and underlying mechanism of CG200745 in high-fat diet (HFD)-induced hypertension. Nine-week old C57BL\/6 mice were fed a normal diet (ND) or HFD for 17 weeks. Each group of mice was treated with vehicle or CG200745 by intraperitoneal injection for 9 days. HFD group showed higher body weight, blood pressure (BP), HDAC activities, angiotensinogen and renin expressions in kidney, angiotensin-converting enzyme (ACE) expression in the lung, serum angiotensin II (Ang II) concentration, and myosin light chain<jats:sub>20<\/jats:sub> (MLC<jats:sub>20<\/jats:sub>) phosphorylation in mesenteric artery compared with ND group. CG200745 lowered BP, HDAC activity, renin and angiotensinogen in the kidney, ACE in the lung, serum Ang II level, and phosphorylation of MLC<jats:sub>20<\/jats:sub> in HFD group. In conclusion, CG200745 ameliorated HFD-induced hypertension through inhibition of HDAC\/Ang II\/vascular contraction axis. Our results offer CG200745 as a novel therapeutic option for HFD-induced hypertension.<\/jats:p>","DOI":"10.1007\/s00210-019-01749-5","type":"journal-article","created":{"date-parts":[[2019,10,26]],"date-time":"2019-10-26T07:20:51Z","timestamp":1572074451000},"page":"491-500","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Histone deacetylase inhibitor CG200745 ameliorates high-fat diet-induced hypertension via inhibition of angiotensin II production"],"prefix":"10.1007","volume":"393","author":[{"given":"Ga-Eun","family":"Yoon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Ki","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun-Han","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byeong-Churl","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3965-9035","authenticated-orcid":false,"given":"Jee","family":"In Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,10,26]]},"reference":[{"key":"1749_CR1","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.drudis.2015.12.001","volume":"21","author":"AO Arguelles","year":"2016","unstructured":"Arguelles AO, Meruvu S, Bowman JD, Choudhury M (2016) Are epigenetic drugs for diabetes and obesity at our door step? Drug discovery today 21:499\u2013509","journal-title":"Drug discovery today"},{"key":"1749_CR2","unstructured":"Bae EH, Kim IJ, Song JH, Choi HS, Kim CS, Eom GH, Kim I, Cha H, Cho JM, Ma SK, Kim SW (2019) Renoprotective effect of the histone seacetylase inhibitor CG200745 in DOCA-salt hypertensive rats. International journal of molecular sciences 20"},{"key":"1749_CR3","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1172\/JCI112566","volume":"78","author":"DJ Campbell","year":"1986","unstructured":"Campbell DJ, Habener JF (1986) Angiotensinogen gene is expressed and differentially regulated in multiple tissues of the rat. The Journal of clinical investigation 78:31\u201339","journal-title":"The Journal of clinical investigation"},{"key":"1749_CR4","doi-asserted-by":"publisher","first-page":"725","DOI":"10.3892\/ijmm.2015.2263","volume":"36","author":"Y Chen","year":"2015","unstructured":"Chen Y, Cai S, Wang J, Xu M (2015) Valproic acid-induced histone acetylation suppresses CYP19 gene expression and inhibits the growth and survival of endometrial stromal cells. International journal of molecular medicine 36:725\u2013732","journal-title":"International journal of molecular medicine"},{"key":"1749_CR5","first-page":"878","volume":"361","author":"AV Chobanian","year":"2009","unstructured":"Chobanian AV (2009) Shattuck Lecture. The hypertension paradox--more uncontrolled disease despite improved therapy. The New England journal of medicine 361:878\u2013887","journal-title":"The hypertension paradox--more uncontrolled disease despite improved therapy. The New England journal of medicine"},{"key":"1749_CR6","doi-asserted-by":"crossref","unstructured":"Choi J, Park S, Kwon TK, Sohn SI, Park KM, Kim JI (2017) Role of the histone deacetylase inhibitor valproic acid in high-fat diet-induced hypertension via inhibition of HDAC1\/angiotensin II axis. International journal of obesity (2005) 41: 1702-1709","DOI":"10.1038\/ijo.2017.166"},{"key":"1749_CR7","doi-asserted-by":"publisher","first-page":"2801","DOI":"10.1111\/jcmm.14188","volume":"23","author":"SY Choi","year":"2019","unstructured":"Choi SY, Kee HJ, Sun S, Seok YM, Ryu Y, Kim GR, Kee SJ, Pflieger M, Kurz T, Kassack MU, Jeong MH (2019) Histone deacetylase inhibitor LMK235 attenuates vascular constriction and aortic remodelling in hypertension. Journal of cellular and molecular medicine 23:2801\u20132812","journal-title":"Journal of cellular and molecular medicine"},{"key":"1749_CR8","unstructured":"CrystalGenomics (2019) Development of clinical."},{"key":"1749_CR9","unstructured":"Delaney J (2009) Hypertension and obesity: how weight-loss affects hypertension. Obesity Action Coalition"},{"key":"1749_CR10","doi-asserted-by":"crossref","unstructured":"Devin JK, Pretorius M, Nian H, Yu C, Billings FTt, Brown NJ (2014) Substance P increases sympathetic activity during combined angiotensin-converting enzyme and dipeptidyl peptidase-4 inhibition. Hypertension (Dallas, Tex : 1979) 63: 951-957","DOI":"10.1161\/HYPERTENSIONAHA.113.02767"},{"key":"1749_CR11","doi-asserted-by":"crossref","unstructured":"Eckschlager T, Plch J, Stiborova M, Hrabeta J (2017) Histone deacetylase inhibitors as anticancer drugs. International journal of molecular sciences 18","DOI":"10.3390\/ijms18071414"},{"key":"1749_CR12","unstructured":"Food & Drug Administration (2011) High blood pressure-medicines to help you."},{"key":"1749_CR13","doi-asserted-by":"crossref","unstructured":"Hall JE (2003) The kidney, hypertension, and obesity. Hypertension (Dallas, Tex : 1979) 41: 625-633","DOI":"10.1161\/01.HYP.0000052314.95497.78"},{"key":"1749_CR14","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1007\/s10637-011-9718-1","volume":"30","author":"JJ Hwang","year":"2012","unstructured":"Hwang JJ, Kim YS, Kim T, Kim MJ, Jeong IG, Lee JH, Choi J, Jang S, Ro S, Kim CS (2012) A novel histone deacetylase inhibitor, CG200745, potentiates anticancer effect of docetaxel in prostate cancer via decreasing Mcl-1 and Bcl-XL. Investigational new drugs 30:1434\u20131442","journal-title":"Investigational new drugs"},{"key":"1749_CR15","unstructured":"Hyun Y-L, Kim HJ, Kim YE, Lee JH, Lee CH, Jung HJ, Kim JH, Choi E, Shin D-K, Park MG (2009) Abstract# 4561: Preclinical studies of CG200745, novel histone deacetylase inhibitor discovered using structure-based drug discovery technologies. AACR"},{"key":"1749_CR16","doi-asserted-by":"publisher","first-page":"10921","DOI":"10.1038\/s41598-017-11094-3","volume":"7","author":"DE Jung","year":"2017","unstructured":"Jung DE, Park SB, Kim K, Kim C, Song SY (2017) CG200745, an HDAC inhibitor, induces anti-tumour effects in cholangiocarcinoma cell lines via miRNAs targeting the Hippo pathway. Scientific reports 7:10921","journal-title":"Scientific reports"},{"key":"1749_CR17","doi-asserted-by":"crossref","unstructured":"Kelly T, Yang W, Chen CS, Reynolds K, He J (2008) Global burden of obesity in 2005 and projections to 2030. International journal of obesity (2005) 32: 1431-1437","DOI":"10.1038\/ijo.2008.102"},{"key":"1749_CR18","doi-asserted-by":"publisher","first-page":"99","DOI":"10.4196\/kjpp.2017.21.1.99","volume":"21","author":"JI Kim","year":"2017","unstructured":"Kim JI (2017) High fat diet confers vascular hyper-contractility against angiotensin II through upregulation of MLCK and CPI-17. The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology 21:99\u2013106","journal-title":"The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology"},{"key":"1749_CR19","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1007\/s10637-015-0262-2","volume":"33","author":"KP Kim","year":"2015","unstructured":"Kim KP, Park SJ, Kim JE, Hong YS, Lee JL, Bae KS, Cha H, Kwon SK, Ro S, Cho J, Kim TW (2015) First-in-human study of the toxicity, pharmacokinetics, and pharmacodynamics of CG200745, a pan-HDAC inhibitor, in patients with refractory solid malignancies. Investigational new drugs 33:1048\u20131057","journal-title":"Investigational new drugs"},{"key":"1749_CR20","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.amjhyper.2003.09.014","volume":"17","author":"JB Kostis","year":"2004","unstructured":"Kostis JB, Packer M, Black HR, Schmieder R, Henry D, Levy E (2004) Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. American journal of hypertension 17:103\u2013111","journal-title":"American journal of hypertension"},{"key":"1749_CR21","doi-asserted-by":"crossref","unstructured":"Lee E, Lee HA, Kim M, Do GY, Cho HM, Kim GJ, Jung H, Song JH, Cho JM, Kim I (2018) Upregulation of C\/EBPbeta and TSC2 by an HDAC inhibitor CG200745 protects heart from DOCA-induced hypertrophy. Clinical and experimental pharmacology & physiology","DOI":"10.1111\/1440-1681.13022"},{"key":"1749_CR22","doi-asserted-by":"publisher","first-page":"477","DOI":"10.4196\/kjpp.2016.20.5.477","volume":"20","author":"E Lee","year":"2016","unstructured":"Lee E, Song MJ, Lee HA, Kang SH, Kim M, Yang EK, Lee Do Y, Ro S, Cho JM, Kim I (2016) Histone deacetylase inhibitor, CG200745, attenuates cardiac hypertrophy and fibrosis in DOCA-induced hypertensive rats. The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology 20:477\u2013485","journal-title":"The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology"},{"key":"1749_CR23","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1161\/CIRCRESAHA.113.301071","volume":"112","author":"HA Lee","year":"2013","unstructured":"Lee HA, Lee DY, Cho HM, Kim SY, Iwasaki Y, Kim IK (2013) Histone deacetylase inhibition attenuates transcriptional activity of mineralocorticoid receptor through its acetylation and prevents development of hypertension. Circulation research 112:1004\u20131012","journal-title":"Circulation research"},{"key":"1749_CR24","doi-asserted-by":"crossref","unstructured":"Mark AL, Correia M, Morgan DA, Shaffer RA, Haynes WG (1999) State-of-the-art-lecture: Obesity-induced hypertension: new concepts from the emerging biology of obesity. Hypertension (Dallas, Tex : 1979) 33: 537-541","DOI":"10.1161\/01.HYP.33.1.537"},{"key":"1749_CR25","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3810\/pgm.2009.11.2074","volume":"121","author":"X Pi-Sunyer","year":"2009","unstructured":"Pi-Sunyer X (2009) The medical risks of obesity. Postgraduate medicine 121:21\u201333","journal-title":"Postgraduate medicine"},{"issue":"Suppl 3","key":"1749_CR26","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1038\/sj.ijo.0802804","volume":"28","author":"BM Popkin","year":"2004","unstructured":"Popkin BM, Gordon-Larsen P (2004) The nutrition transition: worldwide obesity dynamics and their determinants. International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity 28(Suppl 3):S2\u2013S9","journal-title":"International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity"},{"key":"1749_CR27","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1210\/en.2005-1030","volume":"147","author":"L Qiao","year":"2006","unstructured":"Qiao L, Schaack J, Shao J (2006) Suppression of adiponectin gene expression by histone deacetylase inhibitor valproic acid. Endocrinology 147:865\u2013874","journal-title":"Endocrinology"},{"key":"1749_CR28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0213186","volume":"14","author":"Y Ryu","year":"2019","unstructured":"Ryu Y, Kee HJ, Sun S, Seok YM, Choi SY, Kim GR, Kee SJ, Pflieger M, Kurz T, Kim HS, Jeong MH (2019) Class I histone deacetylase inhibitor MS-275 attenuates vasoconstriction and inflammation in angiotensin II-induced hypertension. PloS one 14:e0213186","journal-title":"PloS one"},{"key":"1749_CR29","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1007\/s11906-018-0900-0","volume":"20","author":"R Satou","year":"2018","unstructured":"Satou R, Penrose H, Navar LG (2018) Inflammation as a regulator of the renin-angiotensin system and blood pressure. Current hypertension reports 20:100","journal-title":"Current hypertension reports"},{"key":"1749_CR30","doi-asserted-by":"publisher","first-page":"873","DOI":"10.2146\/ajhp150482","volume":"73","author":"MJ Scalese","year":"2016","unstructured":"Scalese MJ, Reinaker TS (2016) Pharmacologic management of angioedema induced by angiotensin-converting enzyme inhibitors. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 73:873\u2013879","journal-title":"American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists"},{"key":"1749_CR31","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1161\/hc4101.096153","volume":"104","author":"AC Schoolwerth","year":"2001","unstructured":"Schoolwerth AC, Sica DA, Ballermann BJ, Wilcox CS (2001) Renal considerations in angiotensin converting enzyme inhibitor therapy: a statement for healthcare professionals from the Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association. Circulation 104:1985\u20131991","journal-title":"Circulation"},{"key":"1749_CR32","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1161\/01.RES.0000059987.90200.44","volume":"92","author":"T Seko","year":"2003","unstructured":"Seko T, Ito M, Kureishi Y, Okamoto R, Moriki N, Onishi K, Isaka N, Hartshorne DJ, Nakano T (2003) Activation of RhoA and inhibition of myosin phosphatase as important components in hypertension in vascular smooth muscle. Circulation research 92:411\u2013418","journal-title":"Circulation research"},{"key":"1749_CR33","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1056\/NEJM199208203270808","volume":"327","author":"JF Setaro","year":"1992","unstructured":"Setaro JF, Black HR (1992) Refractory hypertension. The New England journal of medicine 327:543\u2013547","journal-title":"The New England journal of medicine"},{"key":"1749_CR34","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1002\/cphy.c130040","volume":"4","author":"MA Sparks","year":"2014","unstructured":"Sparks MA, Crowley SD, Gurley SB, Mirotsou M, Coffman TM (2014) Classical renin-angiotensin system in kidney physiology. Comprehensive Physiology 4:1201\u20131228","journal-title":"Comprehensive Physiology"},{"key":"1749_CR35","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.jss.2013.10.050","volume":"187","author":"M Takebe","year":"2014","unstructured":"Takebe M, Oishi H, Taguchi K, Aoki Y, Takashina M, Tomita K, Yokoo H, Takano Y, Yamazaki M, Hattori Y (2014) Inhibition of histone deacetylases protects septic mice from lung and splenic apoptosis. The Journal of surgical research 187:559\u2013570","journal-title":"The Journal of surgical research"},{"key":"1749_CR36","doi-asserted-by":"crossref","unstructured":"Tang J, Yan H, Zhuang S (2013) Histone deacetylases as targets for treatment of multiple diseases. Clinical science (London, England : 1979) 124: 651-662","DOI":"10.1042\/CS20120504"},{"key":"1749_CR37","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1007\/s11906-012-0245-z","volume":"14","author":"T Thethi","year":"2012","unstructured":"Thethi T, Kamiyama M, Kobori H (2012) The link between the renin-angiotensin-aldosterone system and renal injury in obesity and the metabolic syndrome. Current hypertension reports 14:160\u2013169","journal-title":"Current hypertension reports"},{"key":"1749_CR38","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1093\/cvr\/cvy023","volume":"114","author":"RM Touyz","year":"2018","unstructured":"Touyz RM, Alves-Lopes R, Rios FJ, Camargo LL, Anagnostopoulou A, Arner A, Montezano AC (2018) Vascular smooth muscle contraction in hypertension. Cardiovascular research 114:529\u2013539","journal-title":"Cardiovascular research"},{"key":"1749_CR39","first-page":"641979","volume":"2014","author":"Y Wang","year":"2014","unstructured":"Wang Y, Miao X, Liu Y, Li F, Liu Q, Sun J, Cai L (2014) Dysregulation of histone acetyltransferases and deacetylases in cardiovascular diseases. Oxidative medicine and cellular longevity 2014:641979","journal-title":"Oxidative medicine and cellular longevity"},{"key":"1749_CR40","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1016\/j.bbadis.2010.05.002","volume":"1802","author":"A Wirth","year":"2010","unstructured":"Wirth A (2010) Rho kinase and hypertension. Biochimica et biophysica acta 1802:1276\u20131284","journal-title":"Biochimica et biophysica acta"},{"key":"1749_CR41","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1159\/000499597","volume":"49","author":"TC Woods","year":"2019","unstructured":"Woods TC, Satou R, Miyata K, Katsurada A, Dugas CM, Klingenberg NC, Fonseca VA, Navar LG (2019) Canagliflozin prevents intrarenal angiotensinogen augmentation and mitigates kidney injury and hypertension in mouse model of type 2 diabetes mellitus. American journal of nephrology 49:331\u2013342","journal-title":"American journal of nephrology"},{"key":"1749_CR42","unstructured":"World Health Organization (2018) Obesity and overweight."},{"key":"1749_CR43","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1097\/00007890-200108150-00035","volume":"72","author":"A Yildiz","year":"2001","unstructured":"Yildiz A, Cine N, Akkaya V, Sahin S, Ismailoglu V, Turk S, Bozfakioglu S, Sever MS (2001) Comparison of the effects of enalapril and losartan on posttransplantation erythrocytosis in renal transplant recipients: prospective randomized study. Transplantation 72:542\u2013544","journal-title":"Transplantation"},{"key":"1749_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4068\/cmj.2016.52.1.1","volume":"52","author":"S Yoon","year":"2016","unstructured":"Yoon S, Eom GH (2016) HDAC and HDAC inhibitor: from cancer to cardiovascular diseases. Chonnam medical journal 52:1\u201311","journal-title":"Chonnam medical journal"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-019-01749-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00210-019-01749-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-019-01749-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,24]],"date-time":"2020-10-24T23:04:43Z","timestamp":1603580683000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00210-019-01749-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,26]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["1749"],"URL":"https:\/\/doi.org\/10.1007\/s00210-019-01749-5","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,26]]},"assertion":[{"value":"25 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All animal experiments were conducted in accordance with the guidelines of the National Institutes of Health for the care and use of laboratory animals. The experimental protocol (KM-2017-34R1) was approved by the Institutional Animal Care and Use Committee at Keimyung University.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}